Delivery Order SPE2DB20D2104-SPE2DB25FMNGF

Award Date 4/11/25
Potential Completion Date 4/14/25
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,441.80, is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of April 15, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,257.52, is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,396.82, is for the delivery of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of April 1, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,362.27, is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract type is Delivery Order with a Firm Fixed Price pricing model. The award has no set-aside designation, indicating open competition. The contract has an ultimate completion date of March 31, 2025....
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,038.07, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.6ML, a pharmaceutical product. The contract has a completion date of July 23, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,195.28, is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.8ML, a pharmaceutical product. The contract has a period of performance through July 9, 2024 and was awarded on July 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,367.86, is for the provision of MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award has an ultimate completion date of May 21, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,897.62, is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has a period of performance through March 28, 2025. The award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is valued at $2,630.00 and has an ultimate completion date of November 15, 2024. The contract is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. No set-aside designation was used for this award. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,697.43 contract is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to support federal healthcare programs. The contract has an ultimate completion date of April 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMNGF
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $24,317.05, is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award has an ultimate completion date of April 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award is not designated as a set-aside.

Generated 7/11/25, 9:58 AM